Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2013 · 10-Q
Revenue$14.45M$14.45M+86.3% vs Q2 2012 Net Income-$22.91M-$22.91MN/M vs Q2 2012 EPS Diluted-$0.20-$0.20N/M vs Q2 2012 Gross Profit$1,816,000+375.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$10,955,000N/M Free Cash Flowderived-$11,035,000N/M Margins · derivedGross margin12.6%+7.6 pt vs Q2 2012
Operating margin-153.0%+28.1 pt vs Q2 2012
Net margin-158.5%+22.2 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 7, 2013 · 38 d after period end